Co-Pays For GLP-1 Weight Loss Drugs To Rise If They’re Even Covered
The rising costs of GLP-1 weight loss drugs are significantly impacting employer healthcare expenses. A recent report indicates that these drugs are a major contributor to increasing prescription spending, leading to higher out-of-pocket costs for employees. As a result, employers are reconsidering their coverage options for these medications, with many likely to implement stricter management strategies.
- ▪GLP-1 weight loss drugs like Ozempic and Wegovy are driving up employer healthcare costs.
- ▪The annual cost of insuring a family of four has surpassed $35,000, with employees contributing about $15,000.
- ▪Only 72% of employers covering GLP-1 drugs for weight management are likely to continue that coverage in 2027.
Opening excerpt (first ~120 words) tap to expand
InnovationHealthcareCo-Pays For GLP-1 Weight Loss Drugs To Rise If They’re Even CoveredByBruce Japsen,Senior Contributor.Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy.Follow AuthorMay 24, 2026, 09:52am EDT--:-- / --:--This voice experience is generated by AI. Learn more.This voice experience is generated by AI. Learn more.Photo Illustration of the new Wegovy semaglutide tablets with injectable prescription weight loss medicines, Ozempic, Victoza and Wegovy. Its a prescription medicine used with a reduced calorie diet and physical activity.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Forbes — Business.
Discussion
0 commentsMore from Forbes — Business
